Comments on: Psych Journal Discloses Editorial Board Conflicts http://www.pharmalot.com/2008/09/psychiatric-times-to-disclose-editorial-board-conflicts/ News, Comment and Conversation Fri, 10 Feb 2012 21:11:47 +0000 http://wordpress.org/?v=2.6.2 By: Ronald Pies MD http://www.pharmalot.com/2008/09/psychiatric-times-to-disclose-editorial-board-conflicts/#comment-382784 Ronald Pies MD Mon, 24 Nov 2008 22:22:49 +0000 http://www.pharmalot.com/?p=15260#comment-382784 Dear Dr. Pies, As you might have seen, we ran a correction in Integrity in Science Watch this week: (www.cspinet.org/integrity/watch/index.html) Corrections and Clarifications The Sept. 2, 2008 issue of Integrity in Science Watch incorrectly linked Robert Freedman, editor-in-chief of the American Journal of Psychiatry, to a financial disclosure for Robert R. Freedman, a professor of psychiatry at Wayne State University in Michigan. We apologize for the error. That same issue and story reported that Ronald Pies, editor-in-chief of Psychiatric Times, received education grants or consulting fees from pharmaceutical companies. Dr. Pies reports that he has received no money from the drug industry in the past 18 months, which coincides with his tenure as editor. While Integrity in Science Watch uses a five-year look-back period for reporting conflicts of interest and believes these relationships should have been disclosed to readers of Psychiatric Times, the use of the present tense in the story was incorrect. We apologize for the error. Dear Dr. Pies,

As you might have seen, we ran a correction in Integrity in Science Watch this week: (www.cspinet.org/integrity/watch/index.html)

Corrections and Clarifications

The Sept. 2, 2008 issue of Integrity in Science Watch incorrectly linked Robert Freedman, editor-in-chief of the American Journal of Psychiatry, to a financial disclosure for Robert R. Freedman, a professor of psychiatry at Wayne State University in Michigan. We apologize for the error.

That same issue and story reported that Ronald Pies, editor-in-chief of Psychiatric Times, received education grants or consulting fees from pharmaceutical companies. Dr. Pies reports that he has received no money from the drug industry in the past 18 months, which coincides with his tenure as editor. While Integrity in Science Watch uses a five-year look-back period for reporting conflicts of interest and believes these relationships should have been disclosed to readers of Psychiatric Times, the use of the present tense in the story was incorrect. We apologize for the error.

]]> By: Ronald Pies MD http://www.pharmalot.com/2008/09/psychiatric-times-to-disclose-editorial-board-conflicts/#comment-377142 Ronald Pies MD Thu, 02 Oct 2008 17:21:42 +0000 http://www.pharmalot.com/?p=15260#comment-377142 P.S. I also would like to note that I no longer accept any stipends or speakers' honoraria from any pharmaceutical companies. --Ronald Pies MD P.S. I also would like to note that I no longer accept any stipends or speakers’ honoraria from any pharmaceutical companies. –Ronald Pies MD

]]> By: Ronald Pies MD http://www.pharmalot.com/2008/09/psychiatric-times-to-disclose-editorial-board-conflicts/#comment-377024 Ronald Pies MD Wed, 01 Oct 2008 06:09:37 +0000 http://www.pharmalot.com/?p=15260#comment-377024 The author of the article should have done his homework and not relied on 3-year-old information about me. At present, I do not receive any regular monies, research support, or stipends from pharmaceutical companies; I belong to no speakers bureaus associated with these companies; and I own no stocks in these companies. Over the past three years, it's possible that one or two lectures received some modest support from a pharmaceutical company--probably not amounting to more than $2000 in a given year. My work with Psychiatric Times is insulated from the "business" side of the paper, and I never have any contact with advertisers. It is nevertheless true that any editor whose publication accepts advertising from drug companies always has a potential conflict of interest, and I acknowledge this in the disclosure statement that will soon be posted on the Psychiatric Times website. Rather than launch ad hominem attacks, I would hope your readers will take a look at our publication and judge the quality of the work for themselves.--Ronald Pies MD The author of the article should have done his homework and not relied on 3-year-old information about me. At present, I do not receive any regular monies, research support, or stipends from pharmaceutical companies; I belong to no speakers bureaus associated with these companies; and I own no stocks in these companies. Over the past three years, it’s possible that one or two lectures received some modest support from a pharmaceutical company–probably not amounting to more than $2000 in a given year. My work with Psychiatric Times is insulated from the “business” side of the paper, and I never have any contact with advertisers. It is nevertheless true that any editor whose publication accepts advertising from drug companies always has a potential conflict of interest, and I acknowledge this in the disclosure statement that will soon be posted on the Psychiatric Times website. Rather than launch ad hominem attacks, I would hope your readers will take a look at our publication and judge the quality of the work for themselves.–Ronald Pies MD

]]> By: truthman30 http://www.pharmalot.com/2008/09/psychiatric-times-to-disclose-editorial-board-conflicts/#comment-371060 truthman30 Wed, 03 Sep 2008 14:58:05 +0000 http://www.pharmalot.com/?p=15260#comment-371060 Autistic children deserve better than this... http://www.namiscc.org/News/2005/Winter/RisperdalMisleadingClaims.htm Risperdal Manufacturer Admits Misleading Claims Schizophrenia Drug Maker Admits To Making Misleading Claims July 25, 2004 A major US drug maker that produces a popular medicine for schizophrenia is acknowledging that it minimized the risks and made misleading claims in promotional materials for the drug, according to reports. Janssen Pharmaceutica Products LP, the maker of Risperdal, has sent a letter to health care providers to clarify the risks involved with the use of Risperdal, according to a Associated Press report. The move comes after the US Federal Drug Administration issued a warning letter to Janssen Pharmaceutica to update their product information. The FDA said Janssen Pharmaceutica made misleading claims and omitted information regarding hypoglycemia and diabetes. The warning letter also stated Janssen Pharmaceutica had made misleading claims that 'Risperdal is safer than other atypical antipsychotics'. "Risperdal is indicated for the treatment of schizophrenia and for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Risperdal is also indicated in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder," according to background information on the drug Risperdal, issued by the FDA in its warning letter. Worldwide, Risperdal is prescribed to more than 10 million people and accounts for about $2 billion in annual sales. Autistic children deserve better than this…

http://www.namiscc.org/News/2005/Winter/RisperdalMisleadingClaims.htm

Risperdal Manufacturer Admits Misleading Claims

Schizophrenia Drug Maker Admits To Making Misleading Claims

July 25, 2004

A major US drug maker that produces a popular medicine for schizophrenia is acknowledging that it minimized the risks and made misleading claims in promotional materials for the drug, according to reports.

Janssen Pharmaceutica Products LP, the maker of Risperdal, has sent a letter to health care providers to clarify the risks involved with the use of Risperdal, according to a Associated Press report.

The move comes after the US Federal Drug Administration issued a warning letter to Janssen Pharmaceutica to update their product information. The FDA said Janssen Pharmaceutica made misleading claims and omitted information regarding hypoglycemia and diabetes.

The warning letter also stated Janssen Pharmaceutica had made misleading claims that ‘Risperdal is safer than other atypical antipsychotics’.

“Risperdal is indicated for the treatment of schizophrenia and for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Risperdal is also indicated in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder,” according to background information on the drug Risperdal, issued by the FDA in its warning letter.

Worldwide, Risperdal is prescribed to more than 10 million people and accounts for about $2 billion in annual sales.

]]> By: truthman30 http://www.pharmalot.com/2008/09/psychiatric-times-to-disclose-editorial-board-conflicts/#comment-371044 truthman30 Wed, 03 Sep 2008 13:20:10 +0000 http://www.pharmalot.com/?p=15260#comment-371044 Supremacy Claus "I want you to teach us how to manage them Risperdal free" You speak of these kids as if they were animals or wild dogs which could only be restrained by using drugs... These are children , not wild and rabid wolves... Maybe you should put them in cages? ... I'm sure if psychiatry could get away with that one they would ... Supremacy Claus

“I want you to teach us how to manage them Risperdal free”

You speak of these kids as if they were animals or wild dogs which could only be restrained by using drugs…

These are children , not wild and rabid wolves…

Maybe you should put them in cages? …

I’m sure if psychiatry could get away with that one they would …

]]> By: Supremacy Claus http://www.pharmalot.com/2008/09/psychiatric-times-to-disclose-editorial-board-conflicts/#comment-371030 Supremacy Claus Wed, 03 Sep 2008 10:38:41 +0000 http://www.pharmalot.com/?p=15260#comment-371030 Truthman: Where do you live? Coming over with a class of ultra violent and self-injurious autistic kids. I want you to teach us how to manage them Risperdal free. I would like to hear your opinion after you have been repeatedly bitten, kicked, pinched, punched, but not allowed to hit them back. If one suffers a serious injury at the hand of another, you may be sued. If you suffer a serious injury at the hand of another, you may not sue. Then, you may second guess parents and teachers who face these children year in, year out. Truthman: Where do you live? Coming over with a class of ultra violent and self-injurious autistic kids. I want you to teach us how to manage them Risperdal free. I would like to hear your opinion after you have been repeatedly bitten, kicked, pinched, punched, but not allowed to hit them back. If one suffers a serious injury at the hand of another, you may be sued. If you suffer a serious injury at the hand of another, you may not sue.

Then, you may second guess parents and teachers who face these children year in, year out.

]]> By: truthman30 http://www.pharmalot.com/2008/09/psychiatric-times-to-disclose-editorial-board-conflicts/#comment-370956 truthman30 Tue, 02 Sep 2008 21:40:17 +0000 http://www.pharmalot.com/?p=15260#comment-370956 "One reason pharma likes psychiatry is that it is often relatively easy to get a person with (or without) mental illness on an expensive blockbuster drug for a long time, thus making big bucks from an individual" Thanks Anne .. Yeah, I know a lot about the industry and psychiatry and they are both as bad as each other when it comes to exploiting vulnerable, misinformed and frightened people who for the most part are experiencing traumas and human emotions.. Autism is very poorly understood ,and all these drugs will do is damage... Prescribing anti-psychotics (like Risperdal) to autistic children is psychiatric child abuse... These psychiatric drugs are dangerous enough in the adult Its a total disgrace that the FDA would approve an anti psychotic for the behavioral traits of autism, approving it for CHILDREN with Autism doesn't just lower the ethical bar, it more or less removes ethics from psychiatry altogether.. “One reason pharma likes psychiatry is that it is often relatively easy to get a person with (or without) mental illness on an expensive blockbuster drug for a long time, thus making big bucks from an individual”

Thanks Anne ..

Yeah, I know a lot about the industry and psychiatry and they are both as bad as each other when it comes to exploiting vulnerable, misinformed and frightened people who for the most part are experiencing traumas and human emotions..

Autism is very poorly understood ,and all these drugs will do is damage…

Prescribing anti-psychotics (like Risperdal) to autistic children is psychiatric child abuse…

These psychiatric drugs are dangerous enough in the adult
Its a total disgrace that the FDA would approve an anti psychotic for the behavioral traits of autism, approving it for CHILDREN with Autism doesn’t just lower the ethical bar, it more or less removes ethics from psychiatry altogether..

]]> By: Anne http://www.pharmalot.com/2008/09/psychiatric-times-to-disclose-editorial-board-conflicts/#comment-370940 Anne Tue, 02 Sep 2008 19:57:13 +0000 http://www.pharmalot.com/?p=15260#comment-370940 Thank you, truthman, for living up to your name. The last time I spoke against the psychopharm industry and its killing ways, I was asked if I were a Scientologist. While it is true that the Scientology group particularly goes after psychiatry - they have good reason. But so do I. One reason pharma likes psychiatry is that it is often relatively easy to get a person with (or without) mental illness on an expensive blockbuster drug for a long time, thus making big bucks from an individual. Thank you, truthman, for living up to your name. The last time I spoke against the psychopharm industry and its killing ways, I was asked if I were a Scientologist. While it is true that the Scientology group particularly goes after psychiatry - they have good reason. But so do I.
One reason pharma likes psychiatry is that it is often relatively easy to get a person with (or without) mental illness on an expensive blockbuster drug for a long time, thus making big bucks from an individual.

]]> By: truthman30 http://www.pharmalot.com/2008/09/psychiatric-times-to-disclose-editorial-board-conflicts/#comment-370939 truthman30 Tue, 02 Sep 2008 19:51:44 +0000 http://www.pharmalot.com/?p=15260#comment-370939 "I seem to recall reading some time ago that Psychiatry is the one physician specialty most paid to by the pharmaceteutical industry. That is understandable" Psychiatry is just another wing of the pharmaceutical industry or as renowned psychiatrist and psychiatric critic Dr Peter Breggin says, it is the "psycho-pharmaceutical industrial complex"... Check out Peter Breggin here : http://www.youtube.com/watch?v=eocYUcoWoxM Can you believe that these unscrupulous psychiatrists and the industry would collude in a scam involving the marketing of an anti-psychotic "Risperdal" to autistic children?.. Well, that's just what they have done.... Risperdal is known for its serious side effects in adults suffering from mental health issues, yet it is now approved for autistic children, this is truly disgusting and a new low ... The irony is , if you read the information leaflet on Risperdal , after the long list of dangerous and unpleasant side effects , what does it say?... "Keep out of reach of children" Unbelievable !!! http://www.risperdalautism.com/risperdalautism/isi.html RISPERDAL® (risperidone) is indicated for the treatment of irritability associated with autistic disorder in children and adolescents (ages 5-16 years), including symptoms of aggression towards others, deliberate self-injury, tantrums, and quickly changing moods. IMPORTANT SAFETY INFORMATION FOR RISPERDAL Elderly Patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. RISPERDAL (risperidone) is not approved for the treatment of patients with dementia-related psychosis. The most common adverse reactions observed in all clinical trials with RISPERDAL occurring at a rate of at least 10% were somnolence, increased appetite, fatigue, rhinitis, upper respiratory tract infection, vomiting, coughing, urinary incontinence, increased saliva, constipation, fever, tremors, muscle stiffness, abdominal pain, anxiety, nausea, dizziness, dry mouth, rash, restlessness, and indigestion. Tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with RISPERDAL and similar medications. TD includes uncontrollable movements of the face, tongue, and other parts of the body. The risk of developing TD and the chance that it will become permanent is thought to increase with the length of therapy and the overall dose taken by the patient. This condition can develop after a brief period of therapy at low doses, although this is much less common. There is no known treatment for TD, but it may go away partially or completely if therapy is stopped. High blood sugar and diabetes have been reported with RISPERDAL and similar medications. If the person being treated has diabetes or risk factors such as being overweight or a family history of diabetes, blood sugar testing should be performed at the beginning and throughout treatment with RISPERDAL. Complications of diabetes can be serious and even life threatening. If signs of high blood sugar or diabetes develop, such as being thirsty all the time, going to the bathroom a lot, or feeling weak or hungry, contact your doctor. Neuroleptic Malignant Syndrome (NMS) is a rare and potentially fatal side effect reported with RISPERDAL and similar medications. Call your doctor immediately if the person being treated develops symptoms such as high fever; stiff muscles; shaking; confusion; sweating; changes in pulse, heart rate, or blood pressure; or muscle pain and weakness. Treatment should be stopped if the person being treated has NMS. RISPERDAL should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizures. RISPERDAL and similar medications can raise the blood levels of a hormone known as prolactin, causing a condition known as hyperprolactinemia. Blood levels of prolactin remain elevated with continued use. Some side effects seen with these medications include the absence of a menstrual period; breasts producing milk; the development of breasts by males; and the inability to achieve an erection. The connection between prolactin levels and side effects is unknown. Extrapyramidal Symptoms (EPS) are usually persistent movement disorders or muscle disturbances, such as restlessness, tremors, and muscle stiffness. If you observe any of these symptoms, talk to your healthcare professional. Some people taking RISPERDAL may feel faint or lightheaded when they stand up or sit up too quickly. By standing up or sitting up slowly and following your healthcare professional's dosing instructions, this side effect may be reduced or it may go away over time. Some medications interact with RISPERDAL. Please inform your healthcare professional of any medications or supplements that you are taking. Avoid products containing alcohol while taking RISPERDAL. Inform your healthcare professional if you are already pregnant or if you are planning to get pregnant while taking RISPERDAL. Do not breast-feed if you are taking RISPERDAL. RISPERDAL may affect alertness and motor skills; use caution until the effect of RISPERDAL is known. Keep out of reach of children. For more information, read the Important Product Information by clicking here. http://www.risperdalautism.com/risperdalautism/ “I seem to recall reading some time ago that Psychiatry is the one physician specialty most paid to by the pharmaceteutical industry. That is understandable”

Psychiatry is just another wing of the pharmaceutical industry or as renowned psychiatrist and psychiatric critic Dr Peter Breggin says, it is the “psycho-pharmaceutical industrial complex”…

Check out Peter Breggin here :

http://www.youtube.com/watch?v=eocYUcoWoxM

Can you believe that these unscrupulous psychiatrists and the industry would collude in a scam involving the marketing of an anti-psychotic “Risperdal” to autistic children?..

Well, that’s just what they have done….

Risperdal is known for its serious side effects in adults suffering from mental health issues, yet it is now approved for autistic children, this is truly disgusting and a new low …

The irony is , if you read the information leaflet on Risperdal , after the long list of dangerous and unpleasant side effects , what does it say?…

“Keep out of reach of children”

Unbelievable !!!

http://www.risperdalautism.com/risperdalautism/isi.html

RISPERDAL® (risperidone) is indicated for the treatment of irritability associated with autistic disorder in children and adolescents (ages 5-16 years), including symptoms of aggression towards others, deliberate self-injury, tantrums, and quickly changing moods.

IMPORTANT SAFETY INFORMATION FOR RISPERDAL

Elderly Patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. RISPERDAL (risperidone) is not approved for the treatment of patients with dementia-related psychosis.

The most common adverse reactions observed in all clinical trials with RISPERDAL occurring at a rate of at least 10% were somnolence, increased appetite, fatigue, rhinitis, upper respiratory tract infection, vomiting, coughing, urinary incontinence, increased saliva, constipation, fever, tremors, muscle stiffness, abdominal pain, anxiety, nausea, dizziness, dry mouth, rash, restlessness, and indigestion.

Tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with RISPERDAL and similar medications. TD includes uncontrollable movements of the face, tongue, and other parts of the body. The risk of developing TD and the chance that it will become permanent is thought to increase with the length of therapy and the overall dose taken by the patient. This condition can develop after a brief period of therapy at low doses, although this is much less common. There is no known treatment for TD, but it may go away partially or completely if therapy is stopped.

High blood sugar and diabetes have been reported with RISPERDAL and similar medications. If the person being treated has diabetes or risk factors such as being overweight or a family history of diabetes, blood sugar testing should be performed at the beginning and throughout treatment with RISPERDAL. Complications of diabetes can be serious and even life threatening. If signs of high blood sugar or diabetes develop, such as being thirsty all the time, going to the bathroom a lot, or feeling weak or hungry, contact your doctor.

Neuroleptic Malignant Syndrome (NMS) is a rare and potentially fatal side effect reported with RISPERDAL and similar medications. Call your doctor immediately if the person being treated develops symptoms such as high fever; stiff muscles; shaking; confusion; sweating; changes in pulse, heart rate, or blood pressure; or muscle pain and weakness. Treatment should be stopped if the person being treated has NMS.

RISPERDAL should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizures.

RISPERDAL and similar medications can raise the blood levels of a hormone known as prolactin, causing a condition known as hyperprolactinemia. Blood levels of prolactin remain elevated with continued use. Some side effects seen with these medications include the absence of a menstrual period; breasts producing milk; the development of breasts by males; and the inability to achieve an erection. The connection between prolactin levels and side effects is unknown.

Extrapyramidal Symptoms (EPS) are usually persistent movement disorders or muscle disturbances, such as restlessness, tremors, and muscle stiffness. If you observe any of these symptoms, talk to your healthcare professional.

Some people taking RISPERDAL may feel faint or lightheaded when they stand up or sit up too quickly. By standing up or sitting up slowly and following your healthcare professional’s dosing instructions, this side effect may be reduced or it may go away over time.

Some medications interact with RISPERDAL. Please inform your healthcare professional of any medications or supplements that you are taking. Avoid products containing alcohol while taking RISPERDAL.

Inform your healthcare professional if you are already pregnant or if you are planning to get pregnant while taking RISPERDAL. Do not breast-feed if you are taking RISPERDAL.

RISPERDAL may affect alertness and motor skills; use caution until the effect of RISPERDAL is known.

Keep out of reach of children.

For more information, read the Important Product Information by clicking here.

http://www.risperdalautism.com/risperdalautism/

]]> By: Dan A. http://www.pharmalot.com/2008/09/psychiatric-times-to-disclose-editorial-board-conflicts/#comment-370919 Dan A. Tue, 02 Sep 2008 17:00:52 +0000 http://www.pharmalot.com/?p=15260#comment-370919 I seem to recall reading some time ago that Psychiatry is the one physician specialty most paid to by the pharmaceteutical industry. That is understandable. I seem to recall reading some time ago that Psychiatry is the one physician specialty most paid to by the pharmaceteutical industry. That is understandable.

]]>